Not long after lending its support to a documentary aimed at shining a light on the often-overlooked stories of women with hemophilia, Sanofi is continuing its film-focused collaboration with patient engagement agency Believe Limited. More: Sanofi backs 2 more documentary
read moreThe status of the CDC’s vaccine advisory panel was thrown into further disarray this week after an outspoken member of the ACIP—whose appointment was invalidated by a federal judge Monday—declared that the group was being disbanded before later correcting his
read moreThe new FDA nod makes Rhythm Pharma’s Imcivree the first approved drug for acquired hypothalamic obesity and brings the drug’s first expansion beyond rare genetic-driven obesities. More: Rhythm's Imcivree scores 'transformative' FDA approval in brain damage-related obesity Source: fierce
read moreThe company is working with regulators to ensure stable ongoing supply for the one-time gene therapy, it said in a community letter. More: CSL warns of supply shortfall, treatment delays for hemophilia gene therapy Hemgenix Source: fierce
read moreStill basking in the afterglow of its Wegovy pill launch earlier this year, Novo has achieved another victory as it strives to make the most out of its blockbuster GLP-1 drug in an increasingly pressured obesity market. More: Novo’s Wegovy
read moreCollegium Pharmaceutical will pay $650 million upfront to acquire ADHD drug Azstarys from Corium Therapeutics. The deal, which includes an additional $135 million in potential milestone payments, gives Collegium a second branded ADHD treatment, Azstarys, along with its Jornay PM. More:
read more© 1994 - 2026 B.M. Pharmaceuticals